General information about company	
Scrip code*	524743
NSE Symbol*	FISCHER
MSEI Symbol*	NOTLISTED
ISIN*	INE771F01041
Name of company	Fischer Medical Ventures Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	29-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	25-05-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Healthcare Equipment and supplies
Start date and time of board meeting	29-05-2026 21:00
End date and time of board meeting	29-05-2026 23:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion
Whether the company has any related party?	Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?	Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public	NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.	NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?	No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?	
(b) If answer to above question is No, please explain the reason for not complying.	

Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		29-05-2026
Indicate Company website link for updated RPT policy of the Company		www.fischermv.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		Yes
No. of times funds raised during the quarter		1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	There are no default

Financial Results – Ind-AS			
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-01-2026	01-04-2025
	Date of end of reporting period	31-03-2026	31-03-2026
	Whether results are audited or unaudited	Audited	Audited
	Nature of report standalone or consolidated	Standalone	Standalone
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**		
1	**Income**		
	Revenue from operations	410.76	1739.18
	Other income	43.4	349.34
	Total income	**454.16**	**2088.52**
2	**Expenses**		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	276.83	1195.68
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	4.58	-35.45
(d)	Employee benefit expense	52.39	201.51
(e)	Finance costs	126.55	465.23
(f)	Depreciation, depletion and amortisation expense	43.39	67.86
(g)	**Other Expenses**		
1	Other expenses	967.1	1244.27
	Total other expenses	**967.1**	**1244.27**
	Total expenses	**1470.84**	**3139.1**
3	**Total profit before exceptional items and tax**	**-1016.68**	**-1050.58**
4	Exceptional items	0	0
5	**Total profit before tax**	**-1016.68**	**-1050.58**
6	**Tax expense**		
7	Current tax	9	9
8	Deferred tax	-127.5	-17.29
9	**Total tax expenses**	**-118.5**	**-8.29**
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	**Net Profit Loss for the period from continuing operations**	**-898.18**	**-1042.29**
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	**Net profit (loss) from discontinued operation after tax**	**0**	**0**

15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	**Total profit (loss) for period**	**-898.18**	**-1042.29**	
17	Other comprehensive income net of taxes	0	0	
18	**Total Comprehensive Income for the period**	**-898.18**	**-1042.29**	
19	**Total profit or loss, attributable to**			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	**Total Comprehensive income for the period attributable to**			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	**Details of equity share capital**			
	Paid-up equity share capital	6545.15	6545.15	
	Face value of equity share capital	1	1	
22	Reserves excluding revaluation reserve		0	
23	**Earnings per share**			
i	**Earnings per equity share for continuing operations**			
	Basic earnings (loss) per share from continuing operations	-0.14	-0.16	
	Diluted earnings (loss) per share from continuing operations	-0.13	-0.15	
ii	**Earnings per equity share for discontinued operations**			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	**Earnings per equity share (for continuing and discontinued operations)**			
	Basic earnings (loss) per share from continuing and discontinued operations	-0.14	-0.16	
	Diluted earnings (loss) per share from continuing and discontinued operations	-0.13	-0.15	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	**Disclosure of notes on financial results**	**Textual Information(4)**		

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
	Assets	
1	**Non-current assets**	
	Property, plant and equipment	2.91
	Capital work-in-progress	
	Investment property	
	Goodwill	0
	Other intangible assets	0
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	Non-current financial assets	
	Non-current investments	30354.97
	Trade receivables, non-current	
	Loans, non-current	0
	Other non-current financial assets	
1	Other financial assets	4317.8
2		
3		
4		
5		
	Details of other non-current financial assets	
	Total of other non-current financial assets	**4317.8**
	Total non-current financial assets	**34672.77**
	Deferred tax assets (net)	44.92
	Other non-current assets	
1	Other non-current assets	53.29
2	ROU asset	1133.33
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	**1186.62**

	Total non-current assets	**35907.22**
2	**Current assets**	
	Inventories	41.95
	Current financial asset	
	Current investments	0
	Trade receivables, current	2071.01
	Cash and cash equivalents	113.85
	Bank balance other than cash and cash equivalents	0
	Loans, current	0
	Other current financial assets	
1	Other current financial assets	203.83
2		
3		
4		
5		
	Details of other current financial assets	
	Total of Other current financial assets	**203.83**
	Total current financial assets	**2388.69**
	Current tax assets (net)	9.15
	Other current assets	
1	Other current assets	518.13
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	**518.13**
	Total current assets	**2957.92**
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	**38865.14**
	Equity and liabilities	
1	**Equity**	
	Equity attributable to owners of parent	
	Equity share capital	6545.15
	Other equity	27268.08
	Total equity attributable to owners of parent	**33813.23**
	Non controlling interest	
	Total equity	**33813.23**

2	**Liabilities**	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	1296.96
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	Total Trade payable	
	Other non-current financial liabilities	
1	Lease liabilities	2559.81
2		
3		
4		
5		
	Details of other non-current financial liabilities	
	Total of other non-current financial liabilities	**2559.81**
	Total non-current financial liabilities	**3856.77**
	Provisions, non-current	10.4
	Deferred tax liabilities (net)	
	Deferred government grants, Non-current	
	Other non-current liabilities	
1		
2		
3		
4		
5		
	Details of other non-current liabilities	
	Total of other non-current liabilities	
	Total non-current liabilities	**3867.17**
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	0
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	219.6
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	144.82
	Total Trade payable	**364.42**
	Other current financial liabilities	
1	Lease liabilities	708
2	Other current financial liabilities	69.52

3		
4		
5		
	Details of other current financial liabilities	
	Total of other current financial liabilities	**777.52**
	Total current financial liabilities	**1141.94**
	Other current liabilities	
1	Other current liabilities	29.71
2		
3		
4		
5		
	Details of other current liabilities	
	Total of other current liabilities	**29.71**
	Provisions, current	13.09
	Current tax liabilities (Net)	
	Deferred government grants, Current	
	Total current liabilities	**1184.74**
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	**5051.91**
	Total equity and liabilities	**38865.14**
	Disclosure of notes on assets and liabilities	

Other Comprehensive Income			
	Date of start of reporting period	01-01-2026	01-04-2025
	Date of end of reporting period	31-03-2026	31-03-2026
	Whether results are audited or unaudited	Audited	Audited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss		
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income		

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	-1050.58
2	**Adjustments for reconcile profit (loss)**	
	Adjustments for finance costs	465.09
	Adjustments for decrease (increase) in inventories	-35.45
	Adjustments for decrease (increase) in trade receivables, current	-428.67
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	23.08
	Adjustments for decrease (increase) in other non-current assets	10.3
	Adjustments for other financial assets, non-current	-54.35
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	319.98
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	29.57
	Adjustments for increase (decrease) in other non-current liabilities	0
	Adjustments for depreciation and amortisation expense	67.86
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	5.26
	Adjustments for provisions, non-current	-1.3
	Adjustments for other financial liabilities, current	55.69
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	305.19
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	-3.8

	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	651.13
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	**799.2**
	Net cash flows from (used in) operations	**-251.38**
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	39.26
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	**-290.64**
3	**Cash flows from used in investing activities**	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	1301.67
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	0
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	2.93
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	212.88
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	142.94
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0

	Dividends received	0
	Interest received	47.84
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) investing activities	**-1326.7**
4	**Cash flows from used in financing activities**	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	1314.45
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	1296.96
	Repayments of borrowings	0
	Payments of lease liabilities	622.08
	Dividends paid	27.44
	Interest paid	259.44
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	**1702.45**
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	**85.11**
5	**Effect of exchange rate changes on cash and cash equivalents**	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	**85.11**
	Cash and cash equivalents cash flow statement at beginning of period	28.71
	Cash and cash equivalents cash flow statement at end of period	**113.82**

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

																Additional disclosure of related party trans transaction relates to loans, inter-corporate dep listed entity/subsidiary. These details need to be such transacti				
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Deta
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature advanc interco deposi investr
1	FMV International Ventures Pte Ltd	ZZZZZ9999Z	FMV Holdings Pte Ltd	AAKCT4138R	Ultimate holding Company	Any other transaction	Borrowings		NIL			433.18	0	433.18					
2	FMV International Ventures Pte Ltd	ZZZZZ9999Z	Mercatus Capital Pte. Ltd	ZZZZZ9999Z	Entities with common control	Any other transaction	Borrowings		NIL			38.74	0	38.74					
3	FMV Global Innnovations Pte Ltd	ZZZZZ9999Z	FMV Holdings Pte Ltd	AAKCT4138R	Ultimate holding Company	Any other transaction	Borrowings		NIL			530.5	0	530.5					
4	FMV Global Innnovations Pte Ltd	ZZZZZ9999Z	Mercatus Capital Pte. Ltd	ZZZZZ9999Z	Entities with common control	Any other transaction	Borrowings		NIL			127.03	0	127.03					
5	Fischer Hospitality Sdn. Bdn.	ZZZZZ9999Z	FMV Global Innnovations Pte Ltd	ZZZZZ9999Z	Fellow Subsidiries	Any other transaction	Borrowings		NIL			0.1	0	0.1					
6	FMV Technologies Sdn Bhd	ZZZZZ9999Z	FMV Holdings Pte Ltd	AAKCT4138R	Ultimate holding Company	Any other transaction	Borrowings		NIL			11.61	0	11.61					
7	FMV Global Innnovations Pte Ltd	ZZZZZ9999Z	PT Fischer Pariko Medical Ventures	ZZZZZ9999Z	Subsidiary	Loan			NIL			229.76	0	229.76					
8	Fischer Medical Venture Limited	AAACF0641D	Wondertech Medical Solutions Private Limited	AADCW9648N	Subsidiary	Advance			NIL			0.73	2.23	2.96					
9	Fischer Medical Venture Limited	AAACF0641D	Nanyang Biologics India Private Limited	AAKCN1682J	Subsidiary	Advance			NIL			1.07	2.49	3.56					
10	Time Medical	AAHCT1130G	Wondertech Medical	AADCW9648N	Subsidiary	Advance			NIL			5.5	0	1					

	International Ventures India Pvt Ltd		Solutions Private Limited																
11	Time Medical International Ventures India Pvt Ltd	AAHCT1130G	Nanyang Biologics India Private Limited	AADCW9648N	Subsidiary	Advance			NIL			5	0	0.5					
Total value of transaction during the reporting period												1383.22							

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Bilimoria Mehta & Co	Yes	30-06-2027

Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)	
Mode of Fund Raising	Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)	
Date of Raising Funds	31-03-2026
Amount Raised	105300000
Report filed for Quarter ended	31-03-2026
Monitoring Agency	Applicable
Monitoring Agency Name, if applicable	Infomerics Valuation and Rating Limited
Is there a Deviation / Variation in use of funds raised	No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	
If Yes, Date of shareholder Approval	
Explanation for the Deviation / Variation	
Comments of the Audit Committee after review	
Comments of the auditors, if any	

Signatory Details	
Name of signatory	Balaji Gandla
Designation of person	Company Secretary and Compliance Officer
Place	Chennai
Date	29-05-2026

General information about company	
Scrip code*	524743
NSE Symbol*	FISCHER
MSEI Symbol*	NOTLISTED
ISIN*	INE771F01041
Name of company	Fischer Medical Ventures Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2025
Date of end of financial year	31-03-2026
Date of board meeting when results were approved	29-05-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	25-05-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Single segment
Description of single segment	Healthcare Equipment and supplies
Start date and time of board meeting	29-05-2026 21:00
End date and time of board meeting	29-05-2026 23:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect

Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

Financial Results – Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
	Date of start of reporting period	01-01-2026	01-04-2025	
	Date of end of reporting period	31-03-2026	31-03-2026	
	Whether results are audited or unaudited	Audited	Audited	
	Nature of report standalone or consolidated	Consolidated	Consolidated	
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**			
1	**Income**			
	Revenue from operations	9773.04	30857.56	
	Other income	127.78	1231.37	
	Total income	**9900.82**	**32088.93**	
2	**Expenses**			
(a)	Cost of materials consumed	6209.35	6224.23	
(b)	Purchases of stock-in-trade	690.33	8349.15	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-53.55	-315.59	
(d)	Employee benefit expense	402.13	1509.42	
(e)	Finance costs	360.83	583.4	
(f)	Depreciation, depletion and amortisation expense	92.57	297.93	
(g)	**Other Expenses**			
1	Direct Expense	256.43	5301.23	
2	Other Expenses	2168.03	5480.78	
	Total other expenses	**2424.46**	**10782.01**	

	Total expenses	**10126.12**	**27430.55**	
3	**Total profit before exceptional items and tax**	**-225.3**	**4658.38**	
4	Exceptional items	0	0	
5	**Total profit before tax**	**-225.3**	**4658.38**	
6	**Tax expense**			
7	Current tax	774.32	1663.33	
8	Deferred tax	-288.77	-129.08	
9	**Total tax expenses**	**485.55**	**1534.25**	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	**Net Profit Loss for the period from continuing operations**	**-710.85**	**3124.13**	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
14	**Net profit (loss) from discontinued operation after tax**	**0**	**0**	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	-1.08	-22.19	
16	**Total profit (loss) for period**	**-711.93**	**3101.94**	
17	Other comprehensive income net of taxes	0	5.43	
18	**Total Comprehensive Income for the period**	**-711.93**	**3107.37**	
19	**Total profit or loss, attributable to**			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	**Total Comprehensive income for the period attributable to**			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	**Details of equity share capital**			

	Paid-up equity share capital	6545.15	6545.15	
	Face value of equity share capital	1	1	
22	Reserves excluding revaluation reserve		0	
23	**Earnings per share**			
i	**Earnings per equity share for continuing operations**			
	Basic earnings (loss) per share from continuing operations	-0.11	0.48	
	Diluted earnings (loss) per share from continuing operations	0.1	0.45	
ii	**Earnings per equity share for discontinued operations**			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	**Earnings per equity share (for continuing and discontinued operations)**			
	Basic earnings (loss) per share from continuing and discontinued operations	-0.11	0.48	
	Diluted earnings (loss) per share from continuing and discontinued operations	0.1	0.45	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	**Disclosure of notes on financial results**	**Textual Information(4)**		

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Consolidated
	Assets	
1	**Non-current assets**	
	Property, plant and equipment	1248.33
	Capital work-in-progress	293.4
	Investment property	0
	Goodwill	527.7
	Other intangible assets	0
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets	
	Non-current investments	11770.96
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	
1	Other Financial Asset	5094.87
2		
3		
4		

5		
	Details of other non-current financial assets	
	Total of other non-current financial assets	**5094.87**
	Total non-current financial assets	**16865.83**
	Deferred tax assets (net)	204.86
	Other non-current assets	
1	ROU Asset	1391.21
2	Other non-current assets	4811.01
3		
4		
5		
	Details of other non-current assets	
	Total of other non-current assets	**6202.22**
	Total non-current assets	**25342.34**
2	**Current assets**	
	Inventories	1266.32
	Current financial asset	
	Current investments	0
	Trade receivables, current	28879.8
	Cash and cash equivalents	1188.94
	Bank balance other than cash and cash equivalents	1315.64
	Loans, current	0
	Other current financial assets	
1	Other current financial assets	650.32
2		
3		

4		
5		
	Details of other current financial assets	
	Total of Other current financial assets	**650.32**
	Total current financial assets	**32034.7**
	Current tax assets (net)	9.15
	Other current assets	
1	Other current assets	8448.54
2		
3		
4		
5		
	Details of other current assets	
	Total of other current assets	**8448.54**
	Total current assets	**41758.71**
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	**67101.05**
	Equity and liabilities	
1	**Equity**	
	Equity attributable to owners of parent	
	Equity share capital	6545.15
	Other equity	31893.35
	Total equity attributable to owners of parent	**38438.5**
	Non controlling interest	75.72
	Total equity	**38514.22**

2	**Liabilities**	
	Non-current liabilities	
	Non-current financial liabilities	
	Borrowings, non-current	26.09
	Trade Payables, non-current	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	Total Trade payable	
	Other non-current financial liabilities	
1	Lease liabilities	2659.41
2		
3		
4		
5		
	Details of other non-current financial liabilities	
	Total of other non-current financial liabilities	**2659.41**
	Total non-current financial liabilities	**2685.5**
	Provisions, non-current	98.75
	Deferred tax liabilities (net)	0
	Deferred government grants, Non-current	
	Other non-current liabilities	
1		
2		
3		
4		
5		

	Details of other non-current liabilities	
	Total of other non-current liabilities	
	Total non-current liabilities	**2784.25**
	Current liabilities	
	Current financial liabilities	
	Borrowings, current	7209.92
	Trade Payables, current	
	(A) Total outstanding dues of micro enterprises and small enterprises	1015.87
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	9244.51
	Total Trade payable	**10260.38**
	Other current financial liabilities	
1	Other current financial liabilities	116.94
2	Lease liability	812.11
3		
4		
5		
	Details of other current financial liabilities	
	Total of other current financial liabilities	**929.05**
	Total current financial liabilities	**18399.35**
	Other current liabilities	
1	Short Term Provisions	4310.7
2	Other current liabilities	1342.08
3		
4		
5		
	Details of other current liabilities	

	Total of other current liabilities	**5652.78**
	Provisions, current	0
	Current tax liabilities (Net)	1750.45
	Deferred government grants, Current	
	Total current liabilities	**25802.58**
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	Total liabilities	**28586.83**
	Total equity and liabilities	**67101.05**
	Disclosure of notes on assets and liabilities	

Other Comprehensive Income			
	Date of start of reporting period	01-01-2026	01-04-2025
	Date of end of reporting period	31-03-2026	31-03-2026
	Whether results are audited or unaudited	Audited	Audited
	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
1	(i) Items that will not be reclassified to profit or loss	0.00	0.00
	Total Amount of items that will not be reclassified to profit and loss	0.00	0.00
2	Income tax relating to items that will not be reclassified to profit or loss	0.00	-5.43
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income	0.00	5.43

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2025
	Date of end of reporting period	31-03-2026
	Whether results are audited or unaudited	Audited
	Nature of report standalone or consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	4658.38
2	**Adjustments for reconcile profit (loss)**	
	Adjustments for finance costs	264.6
	Adjustments for decrease (increase) in inventories	-349.95
	Adjustments for decrease (increase) in trade receivables, current	-21576.06
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-5987.28
	Adjustments for decrease (increase) in other non-current assets	329.24
	Adjustments for other financial assets, non-current	-1332.23
	Adjustments for other financial assets, current	78.62
	Adjustments for other bank balances	0
	Adjustments for increase (decrease) in trade payables, current	8194.9
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	167.47
	Adjustments for increase (decrease) in other non-current liabilities	0

	Adjustments for depreciation and amortisation expense	297.83
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	6002.34
	Adjustments for provisions, non-current	43.32
	Adjustments for other financial liabilities, current	69.68
	Adjustments for other financial liabilities, non-current	0
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	0
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	-119.02
	Other adjustments for non-cash items	901.42
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	**-13015.12**
	Net cash flows from (used in) operations	**-8356.74**
	Dividends received	0
	Interest paid	0
	Interest received	0
	Income taxes paid (refund)	1769.9
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	**-10126.64**
3	**Cash flows from used in investing activities**	
	Cash flows from losing control of subsidiaries or other businesses	0

	Cash flows used in obtaining control of subsidiaries or other businesses	11421.87
	Other cash receipts from sales of equity or debt instruments of other entities	0
	Other cash payments to acquire equity or debt instruments of other entities	2719.67
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	0
	Purchase of property, plant and equipment	131.12
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	128
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0

	Dividends received	0
	Interest received	13878.97
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) investing activities	**-521.69**
4	**Cash flows from used in financing activities**	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	1314.45
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	763.89
	Repayments of borrowings	0
	Payments of lease liabilities	375.29
	Dividends paid	27.44
	Interest paid	264.6
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) financing activities	**1411.01**
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes	**-9237.32**
5	**Effect of exchange rate changes on cash and cash equivalents**	
	Effect of exchange rate changes on cash and cash equivalents	0
	Net increase (decrease) in cash and cash equivalents	**-9237.32**

	Cash and cash equivalents cash flow statement at beginning of period	10426.28
	Cash and cash equivalents cash flow statement at end of period	**1188.96**

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Consolidated results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Bilimoria Mehta & Co	Yes	30-06-2027